VINEETLAB
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Vineet Laboratories Approved Resignation Of Satish Pandurang Samant As CEO
May 29 (Reuters) - Vineet Laboratories Ltd VINL.NS:
APPROVED RESIGNATION OF SATISH PANDURANG SAMANT FROM OFFICE OF CEO
Source text for Eikon: ID:nBSE5H7NXM
Further company coverage: VINL.NS
(([email protected];;))
May 29 (Reuters) - Vineet Laboratories Ltd VINL.NS:
APPROVED RESIGNATION OF SATISH PANDURANG SAMANT FROM OFFICE OF CEO
Source text for Eikon: ID:nBSE5H7NXM
Further company coverage: VINL.NS
(([email protected];;))
Vineet Laboratories Appoints Satish Pandurang Samant As CEO
Oct 16 (Reuters) - Vineet Laboratories Ltd VINL.NS:
APPOINTS SATISH PANDURANG SAMANT AS CEO
Source text for Eikon: ID:nBSE9zrhBl
Further company coverage: VINL.NS
(([email protected];))
Oct 16 (Reuters) - Vineet Laboratories Ltd VINL.NS:
APPOINTS SATISH PANDURANG SAMANT AS CEO
Source text for Eikon: ID:nBSE9zrhBl
Further company coverage: VINL.NS
(([email protected];))
India's Vineet Laboratories March-Quarter Profit Rises
May 29 (Reuters) - Vineet Laboratories Ltd VINL.NS:
MARCH-QUARTER PROFIT 35.5 MILLION RUPEES VERSUS 32.8 MILLION RUPEES
MARCH-QUARTER TOTAL INCOME FROM OPERATIONS 572 MILLION RUPEES VERSUS 555.9 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: VINL.NS
(([email protected];))
May 29 (Reuters) - Vineet Laboratories Ltd VINL.NS:
MARCH-QUARTER PROFIT 35.5 MILLION RUPEES VERSUS 32.8 MILLION RUPEES
MARCH-QUARTER TOTAL INCOME FROM OPERATIONS 572 MILLION RUPEES VERSUS 555.9 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: VINL.NS
(([email protected];))
Events:
Rights
Dividend
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vineet Laboratories do?
Vineet Laboratories Limited, formerly known as Ortin Laboratories Limited, is an Indian company established in 2016. It specializes in Drug Intermediates & Bulk Drugs, offering API Intermediates, Fine Chemicals, Reagents, and Research & Development.
Who are the competitors of Vineet Laboratories?
Vineet Laboratories major competitors are Biofil Chem & Pharma, Vivo Bio Tech, Vivimed Labs, Shanmuga Hospital, Bacil Pharma, Mangalam Drugs&Org., Godavari Drugs. Market Cap of Vineet Laboratories is ₹60 Crs. While the median market cap of its peers are ₹61 Crs.
Is Vineet Laboratories financially stable compared to its competitors?
Vineet Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Vineet Laboratories is 0.49 and is ranked 6 out of its 8 competitors.
Does Vineet Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vineet Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Vineet Laboratories allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Vineet Laboratories balance sheet?
Vineet Laboratories balance sheet is weak and might have solvency issues
Is the profitablity of Vineet Laboratories improving?
The profit is oscillating. The profit of Vineet Laboratories is -₹16.7 Crs for TTM, -₹20.19 Crs for Mar 2025 and ₹1.03 Crs for Mar 2024.
Is the debt of Vineet Laboratories increasing or decreasing?
Yes, The net debt of Vineet Laboratories is increasing. Latest net debt of Vineet Laboratories is ₹42.13 Crs as of Sep-25. This is greater than Mar-25 when it was ₹38.8 Crs.
Is Vineet Laboratories stock expensive?
Vineet Laboratories is not expensive. Latest PE of Vineet Laboratories is 0, while 3 year average PE is 41.42. Also latest EV/EBITDA of Vineet Laboratories is 0.0 while 3yr average is 10.56.
Has the share price of Vineet Laboratories grown faster than its competition?
Vineet Laboratories has given lower returns compared to its competitors. Vineet Laboratories has grown at ~-16.32% over the last 4yrs while peers have grown at a median rate of -16.0%
Is the promoter bullish about Vineet Laboratories?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Vineet Laboratories is 12.46% and last quarter promoter holding is 15.89%
Are mutual funds buying/selling Vineet Laboratories?
There is Insufficient data to gauge this.
